Table 1.
Clinical Information of miRNA Drugs
| Drug Name | Target(s)/Employed miRNA(s) | Current Status | Condition(s) | Company |
|---|---|---|---|---|
| Lademirsen (SAR339375, RG-012) | miR-21 | II | Alport syndrome | Genzyme |
| MRG-201 (Remlarsen) | miR-29 | II | Keloid | miRagen Therapeutics, Inc. |
| RG-125 (AZD4076) | miR-103/107 | II | Nonalcoholic fatty liver disease | AstraZeneca |
| MRG-106 | miR-155 | I | Lymphomas; leukemias | miRagen Therapeutics, Inc. |
| MRG-110 | miR-92a | I | Skin excisional wound | miRagen Therapeutics, Inc. |
| MesomiR 1 | miR-16 | Suspended | Malignant pleural mesothelioma; non-small-cell lung cancer | Asbestos Diseases Research Foundation |
| Miravirsen | miR-122 | Suspended | Chronic hepatitis C | Santaris Pharma A/S |
| RG-101 | miR-122 | Discontinued | Chronic hepatitis C | Regulus Therapeutics Inc. |
| pSil-miR200c and PMIS miR200a | miR-200a/c | Discontinued | Tooth extraction status nos | University of Iowa |
| MRX34 | miR-34a | Discontinued | Melanoma; primary liver cancer; hematologic malignancies | Mirna Therapeutics, Inc. |